Licensing Opportunities
Our most valuable disruptive technologies with real-world potential are matured through our Validation and Institute Project programs. These projects represent a subset of Wyss Institute technologies currently available for licensing. These technologies have been considerably de-risked by our Advanced Technology and Business Development teams and continue to be refined to advance their near-term translation into commercial products that will transform medicine and create a more sustainable world.
Explore Featured Projects
-
Validation Project
NodeTX: Growing lymph nodes to treat cancerNodeTX is a novel immunotherapy that leverages the human body's innate ability to grow lymph nodes to fight tumors. -
Featured Project
Extracellular Vesicles for Biomarker DetectionA non-invasive method to identify biomarkers of disease across cell types and develop diagnostics and monitoring systems. -
Featured Project
Instrument-Free Molecular DiagnosticsA synthetic biology-based molecular diagnostics platform that enables the creation of low-cost, highly accurate tests for non-clinical settings. -
Featured Project
Catalytic Materials: Cheaper, Better Air Purification for a Healthier WorldOur catalytic materials are inspired by the nanostructure of butterfly wings and enable affordable air purification for a variety of applications. -
Validation Project
Lactation Biologics: Increasing Milk Production for Healthier BabiesLactation Biologics is developing a long-lasting, self-injectable treatment to help nursing mothers feed their babies naturally, helping them get the best nutrition possible in the face of climate disasters and supply chain disruptions. -
Featured Project
DNA Nanostructures for Drug DeliveryResearchers at the Wyss Institute have developed two methods for building arbitrarily shaped nanostructures using DNA, with a focus on translating the technology towards nanofabrication and drug delivery applications. One proprietary nanofabrication technique, called “DNA-brick self-assembly,” uses short, synthetic strands of DNA that work like interlocking Lego® bricks. It capitalizes on the ability to program... -
Featured Project
eRapid: Multiplexed Electrochemical Sensors for Fast, Accurate, Portable DiagnosticsHandheld electrochemical sensors have revolutionized at-home medical testing for diabetics, but they have not yet been successfully applied to diagnosing other conditions. These sensors are based on the activity of an enzyme, and there are only a limited number of enzymes that can be used to detect biomarkers of human disease. An alternative, much more... -
Featured Project
Paper-Based DiagnosticsWith the imminent threat of new pandemics and frequent disease outbreaks exemplified by the recent Ebola and Zika epidemics, there is a growing need for low-cost, easily deployable and simple-to-use diagnostic tools. The Wyss Institute has developed paper-based synthetic gene networks as a next generation diagnostic technology for use in global healthcare crises and patient... -
Validation Project
directEsense: Revolutionizing Animal Diagnostic Testing at the Point-of-CareElectrochemical biosensors using a novel surface chemistry offer new opportunities for portable diagnostics with the potential to detect many disease biomarkers in animals and beyond. -
Validation Project
Ichor: Reversing AgingIchor is addressing multiple age-related diseases by identifying genetic interventions that reprogram old cells to a younger state. Therapies based on these interventions could improve survival for cancer patients and long-term cardiovascular and neurological health. -
Validation Project
AquaPulse: Portable Off-the-Grid Water PurificationGlobally, more than 2 billion people are forced to use a drinking water source that is contaminated with bacteria, parasites, and other pathogens, and an estimated 502,000 people die each year from diarrhea as a result of unsafe water. While a majority of the world has access to improved water sources, many are often contaminated;... -
Validation Project
HarborSite: Precise and Efficient Gene Editing for Next-Generation Gene TherapiesThe HarborSite next-generation gene therapy platform enables integration of therapeutic genes into genomic safe harbors using highly specific and efficient recombinases to enable more predictable, safe and durable gene therapies. -
Validation Project
Metabolically Labeled CAR-T Cells Against CancerThrough a simple and effective metabolic labeling approach, patient-derived T cells engineered to carry immune-enhancing cytokines on their surfaces could help expand adoptive T cell therapies to treatment of solid tumors and improve blood cancer therapies. -
Validation Project
Immunostimulatory RNA Therapeutic for Treatment of Cancer and Infectious DiseaseOur novel dsRNAs stimulate the immune system to inhibit cancer, bacterial, and viral infections including SARS-CoV-2 and multiple influenza strains. -
Institute Project
ReConstruct: Vascularized tissue for breast reconstruction and augmentationReConstruct is a platform for growing, vascularizing, and implanting patient-derived tissues that enable safer breast reconstruction after cancer surgery. -
Validation Project
AminoX: Making Better Protein Drugs, Quicker and CheaperAminoX enables protein drugs to only become active in the tumor microenvironment and not elsewhere in the body to avoid immune-related adverse effects in the body. By designing and building non-standard amino acids into strategic positions of protein drugs, AminoX provides tumor-specific, and longer-lasting target inhibition. -
Validation Project
Single-Cell Encapsulation for Improved Cell TherapiesThe Problem Mesenchymal stromal cells (MSCs) are valued for their ability to secrete compounds that modulate the body’s immune system, making them an attractive solution for existing problems with cell therapies including host-vs-graft disease and organ transplant rejections. However, MSCs are rapidly cleared from the body and can come under fire from the immune system.... -
Institute Project
DoriVac: DNA Origami-Based Vaccines for Combination ImmunotherapyPersonalized cancer and infectious disease vaccine platform harnessing DNA nanotechnology to control the co-delivery and co-presentation of tumor antigen and adjuvant ligands to immune cells with nanoscale precision. This approach has potential to trigger enhanced immune responses against tumors and infectious pathogens. -
Validation Project
SomaCode: Getting Cell Therapies Where They Need to GoSomaCode is solving the problem of cell therapy delivery by identifying unique molecular “zip codes” for disease and engineering cells to home to those zip codes, making cell therapies safer and more effective. -
Validation Project
DNA Nanoswitches: "Lab-on-a-Molecule” Drug DiscoveryThe Lab-on-a-Molecule platform leverages the Wyss Institute’s DNA nanotechnology technology for the high-throughput, low-cost screening of a wide range of chemical and biologic compounds to enable the discovery of first-in-class therapeutics for various conditions. -
Validation Project
MyoExo: Wearable Muscle-Centric Sensors for Improved Assessment of Neurological DisordersMyoExo is a diagnostic technology based on strain sensors that can accurately detect muscle rigidity in patients with Parkinson’s disease and other neurological disorders. Data obtained with the device continuously from patients could improve the monitoring of treatments, and therapeutic interventions. -
Validation Project
Engineered Live Biotherapeutic Product (eLBP) to Protect the Microbiome from AntibioticseLBP is a safe and cost-effective therapeutic for patients treated with beta-lactam antibiotics that safeguards against the loss of health-essential microbes while preventing the development and spread of antibiotic resistance. -
Validation Project
Crisscross Nanoseed Detection: Nanotechnology-Powered Infectious Disease DiagnosticsThis nanotech-based diagnostic platform uses a unique nucleation mechanism that assembles a DNA "nanoseed" in the presence of a pathogen-derived biomarker that then is amplified within 15 minutes to create a signal for easy detection. It is highly robust, and cost-effective, and can be adapted to detect a variety of biomarkers.